Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-03-01
2011-03-01
Stucker, Jeffrey (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S019100, C514S957000, C514S958000
Reexamination Certificate
active
07897575
ABSTRACT:
The invention relates to compositions and methods for treating or preventing vascular dementia in a mammal comprising mucosal administration of an amount of E-selectin polypeptide sufficient to induce bystander immune tolerance in the mammal. Another aspect of the invention relates to compositions useful for treating or preventing vascular dementia.
REFERENCES:
patent: 5081034 (1992-01-01), Bevilacqua et al.
patent: 5948407 (1999-09-01), McGuinness et al.
patent: 6482390 (2002-11-01), Hiscocks et al.
patent: 6974573 (2005-12-01), Lee
patent: 7261896 (2007-08-01), Hallenbeck et al.
patent: 2004/0009125 (2004-01-01), Hallenbeck et al.
patent: 2008/0234196 (2008-09-01), Hallenbeck et al.
patent: 2001264813 (2005-12-01), None
patent: 2005235514 (2005-12-01), None
patent: 1842551 (2007-10-01), None
patent: WO 91/08760 (1991-06-01), None
patent: WO 93/16724 (1993-09-01), None
patent: WO 00/04928 (2000-02-01), None
patent: WO 01/89557 (2001-11-01), None
patent: WO 2004/043361 (2004-05-01), None
patent: WO 2004/056386 (2004-07-01), None
patent: WO 2005/016962 (2005-02-01), None
patent: WO 2006/099006 (2006-09-01), None
patent: WO 2007/028133 (2007-03-01), None
patent: WO 2008/045488 (2008-04-01), None
Becker-Andre et al. Eur. J. Biochem./FEBS, vol. 206, 1992, pp. 401-411.
Abel, “Common condition emerges as possible stroke cause,”HealthLink Medical College of Wisonsin1-3, 2005.
Barsoum et al., “Effect of microencapsulated ampicillin on cell-mediated immune responses in mice,”J. Antimicrob Chemother. 40(5):721-4, 1997.
Burrows et al., “Biological and biophysical characterization of recombinant soluble human E-selectin purified at large scale by reversed-phase high-performance liquid chromatography,”J. Chromatogr B Biomed Appl668(2):219-231, 1995.
Chen et al., “Mucosal tolerance to E-selectin provides cell-mediated protection against ischemic brain injury,”PNAS100(25):15107-15112, 2003.
del Zoppo et al., “Inflammation and Stroke: Putative Role for Cytokines, Adhesion Molecules and iNOS in Brain Response to Ischemia,”Brain Pathology10:95-112, 2000.
Endler et al., “The E-selectin S128R polymorphism is not a risk factor for coronary artery disease in patients with diabetes mellitus type 2,”Thromb Res. 112(1-2):47-50, 2003.
Erkinjuntti, “Vascular Cognitive Impairment and Dementia,”Stroke: Pahtophysiology, Diagnosis, and ManagementChapter 29, 648-660.
Feuerstein et al., “Immune tolerance and Stroke: A turning point,”Stroke33(9):2163-4, 2002.
Hanninen and Harrison, “Mucosal tolerance to prevent type 1 diabetes: can the outcome be improved in humans?”Rev Diabet Stud. 1(3):113-121, 2004.
Huang et al., “Postischemic cerebrovascular E-selectin expression mediates tissue injury in murine stroke,”Stroke31(12):3047-3053, 2000.
Illoh et al., “Mucosal tolerance to E-selectin and response to systemic inflammation,”J Cereb Bllod Flow Metab. 26(12):1538-1550, 2006.
Li et al., “Consensus repeat domains of E-selectin enhance ligand binding,”J Bio Chem. 269(6):4431-4437, 1994.
Matsumiya et al., “Dextran sulfate inhibits E-selectin-mediated neutrophil adhesion to endotoxin-activated vascular endothelial cells,”Life Sciences64(2):PL9-PL17, 1998.
Nakayama et al., “Intranasal administration of E-selectin to induce immunological tolerization can suppress subarachnoid hemorrhage-induced vasospasm implicating immune and inflammatory mechanisms in its genesis,” Brain Res. 1132(1):177-184, 2007.
Sacco et al., “Classification of Ischemic Stroke,”Stroke: Pathophysiology, Diagnosis, and ManagementChapter 4, 61-74.
Simundic et al., “Soluble adhesion molecules in acute ischemic stroke,”Clin Invest Med. 27(2):86-92, 2004.
Sughrue et al., “Anti-adhesion molecule strategies as potential neuroprotective agents in cerebral ischemia: a critical review of the literature,”Inflammation Research53(10):497-508, 2004.
Szalai et al., “The Arthus Reaction in Rodents: Species-Specific Requirement of Complement,”Journal of Immunology, 164:463-468, 2000.
Takeda et al., “Induction of mucosal tolerance to E-selection prevents ischemic and hemorrhagic stroke in spontaneously hypertensive genetically stroke-prone rats,”Stroke33:2156-2164, 2002.
Takeda et al., “In spontaneously hypertensive, genetically stroke-prone rate (SHR-SP), induction of mucosal tolerance to E-selectin prevents ischemic and hemorrhagic stroke,”Stroke Symposium114, 2002.
Ulich et al., “Intratracheal administration of endotoxin and cytokines: VIII LPS induces E-selectin expression; anti-E-selectin and soluble E-selectin inhibit acute inflammation,”Inflammation18(4):389-398, 1994.
Wang et al., “Demonstration of increased endothelial-leukocyte adhesion molecule-1 mRNA expression in rat ischemic cortex,”Stroke26(9):1665-1669, 1995.
Welply et al., “Selectins as potential targets of therapeutic intervention in inflammatory diseases,”Biochim Biophys Acta. 1197(2):215-226, 1994.
Federal Occupational Health, New vaccine may provide hope to people at risk for stroke, 2005.
Hallenbeck John M.
Wakita Hideaki
Gucker Stephen
Klarquist & Sparkman, LLP
Stucker Jeffrey
The United States of America as represented by the Department of
LandOfFree
Treatment and prevention of vascular dementia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment and prevention of vascular dementia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment and prevention of vascular dementia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2744416